APG Asset Management N.V. Lowers Holdings in Charles River Laboratories International, Inc. $CRL

Key Points

• APG Asset Management N.V. has reduced its stake in Charles River Laboratories by 9.3%, now owning 27,300 shares worth approximately $3.8 million.
• A significant increase in investment from other firms has been observed, with Assenagon Asset Management raising its position by 1,721.1%, now owning 570,097 shares valued at about $85.8 million.
• Charles River Laboratories stock recently showed a slight decline of 0.3%, with an average target price from analysts set at $175.69, indicating a consensus rating of "Hold."

APG Asset Management N.V. lessened its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 9.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 27,300 shares of the medical research company's stock after selling 2,804 shares during the quarter. APG Asset Management N.V. owned about 0.06% of Charles River Laboratories International worth $3,804,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the stock. Northwestern Mutual Wealth Management Co. raised its stake in shares of Charles River Laboratories International by 1,366.7% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 24,846 shares of the medical research company's stock worth $3,740,000 after purchasing an additional 23,152 shares during the last quarter. Groupe la Francaise raised its stake in shares of Charles River Laboratories International by 44.6% during the first quarter. Groupe la Francaise now owns 590 shares of the medical research company's stock worth $89,000 after purchasing an additional 182 shares during the last quarter. Compound Planning Inc. raised its stake in shares of Charles River Laboratories International by 16.4% during the first quarter. Compound Planning Inc. now owns 1,879 shares of the medical research company's stock worth $283,000 after purchasing an additional 265 shares during the last quarter. Ameriprise Financial Inc. raised its stake in shares of Charles River Laboratories International by 144.3% during the first quarter. Ameriprise Financial Inc. now owns 544,825 shares of the medical research company's stock worth $82,007,000 after purchasing an additional 321,789 shares during the last quarter. Finally, Norinchukin Bank The raised its stake in shares of Charles River Laboratories International by 13.3% during the first quarter. Norinchukin Bank The now owns 2,554 shares of the medical research company's stock worth $384,000 after purchasing an additional 299 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Price Performance

Shares of CRL stock traded up $0.07 during mid-day trading on Friday, reaching $163.29. The stock had a trading volume of 860,239 shares, compared to its average volume of 954,372. The company has a market cap of $8.04 billion, a P/E ratio of -122.77, a price-to-earnings-growth ratio of 5.21 and a beta of 1.48. The business has a 50-day simple moving average of $159.32 and a 200 day simple moving average of $148.81. Charles River Laboratories International, Inc. has a 12-month low of $91.86 and a 12-month high of $230.02. The company has a current ratio of 1.36, a quick ratio of 1.10 and a debt-to-equity ratio of 0.69.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The medical research company reported $3.12 EPS for the quarter, topping analysts' consensus estimates of $2.50 by $0.62. The firm had revenue of $1.03 billion during the quarter, compared to analysts' expectations of $983.76 million. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%.The firm's quarterly revenue was up .6% compared to the same quarter last year. During the same quarter last year, the business posted $2.80 EPS. On average, sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have issued reports on CRL shares. JPMorgan Chase & Co. increased their price objective on Charles River Laboratories International from $145.00 to $160.00 and gave the stock a "neutral" rating in a research report on Thursday, August 7th. TD Cowen upgraded Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 price objective for the company in a research report on Wednesday, May 14th. Redburn Atlantic upgraded Charles River Laboratories International from a "neutral" rating to a "buy" rating and cut their price objective for the stock from $188.00 to $182.00 in a research report on Friday, May 23rd. Cowen upgraded Charles River Laboratories International from a "hold" rating to a "buy" rating in a research report on Wednesday, May 14th. Finally, Barclays increased their price objective on Charles River Laboratories International from $155.00 to $165.00 and gave the stock an "equal weight" rating in a research report on Thursday, August 7th. Five equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Charles River Laboratories International presently has an average rating of "Hold" and an average price target of $175.69.

Insider Buying and Selling

In related news, EVP Joseph W. Laplume sold 800 shares of Charles River Laboratories International stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $157.60, for a total transaction of $126,080.00. Following the completion of the sale, the executive vice president owned 24,116 shares in the company, valued at approximately $3,800,681.60. This trade represents a 3.21% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 1.30% of the company's stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).